Description: Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Home Page: www.fennecpharma.com
FENC Technical Analysis
68 TW Alexander Drive
Research Triangle Park,
NC
27709
United States
Phone:
919 636 4530
Officers
| Name | Title |
|---|---|
| Mr. Rostislav Raykov | CEO & Director |
| Mr. Robert C. Andrade | Chief Financial Officer |
| Mr. Mark Meier | Sr. VP of Commercial |
| Mr. Mark Gowland | Controller |
| Mr. Lei Fang | Pres of Pharstat Inc |
| Ms. Anne McKay | Regulatory Consultant |
| Mr. Alexander D. Smith M.S. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 92.3152 |
| Price-to-Sales TTM: | 829.8398 |
| IPO Date: | 2001-06-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |